Patent details

LUC00271 Product Name: Combination of daunorubicin and cytarabine

Basic Information

Publication number:
LUC00271
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP172004988
Legal Status:
Inactive
Application number:
LUC00271
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/18/1308
Marketing Authorization Type:
Marketing Authorization Date:
27/08/2018
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
29/06/2022
First Marketing Authorization date:
27/08/2018
Grant date:
25/04/2025
Activation date:
Publication date:
04/07/2022
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
15/02/2033
SPC Extension Expiration:
15/02/2033
Rejection date:
Withdrawal date:

Owner

From:
29/06/2022
 
 

Name:
Rotalec IP Holdings LLC
Address:
3170 Porter Drive, Palo Alto, CA 94304, United States (US)

Agent

Name:
Dennemeyer & Associates S.A.
From:
29/06/2022
Address:
55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2022/09
Publication date:
01/08/2022
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2025/06
Publication date:
12/05/2025
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
29/02/2028
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
29/06/2022 Application Form 5
29/06/2022 General Document 25
29/06/2022 MA publication 13
29/06/2022 Marketing authorization 3
29/06/2022 Summary of the product caracteristics 32
04/07/2022 Outgoing Correspondence 1
04/07/2022 Publication 1
25/04/2025 Publication 1
25/04/2025 Certificate 1
25/04/2025 Outgoing Correspondence 1